Answers are grounded in this paper and cite their sources.
In vitro and in vivo analysis shows ROR1-targeted imaging agents improve tumor visualization and suggest a role in the PI3K/AKT pathway.
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is highly upregulated in multiple cancers and serves as a promising biomarker for patient staging and therapy guidance. We designed five ROR1-targeted radiotracers, including linear and cyclic peptides derived from PR7, and evaluated their specificity and affinity in vitro and in vivo. All probes showed a rapid tumor uptake within 30 min in MC38 models. Saturation binding assays and blocking studies confirmed the ROR1 specificity. Positron emission tomography imaging with [⁶⁸Ga]Ga-DP1 and [¹⁸F]AlF-NP1 demonstrated excellent tumor targeting and favorable target-to-nontarget ratios across multiple models, with renal clearance observed in biodistribution. Transcriptomic analysis indicated the potential involvement of ROR1 in the PI3K/AKT pathway. In general, these findings support [¹⁸F]AlF-NP1 and [⁶⁸Ga]Ga-DP1 as promising noninvasive imaging agents for quantitative ROR1 visualization and personalized cancer therapy.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: